Monitoring the control of human papillomavirus (HPV) infection and related diseases in Australia: Towards a national HPV surveillance strategy

Sexual Health

Volumn 7, Issue 3, 2010, Pages 310-319

  Brotherton, Julia M L ^a,b   Kaldor, John M ^c   Garland, Suzanne M ^d,e,f,g  

^a VICTORIAN CYTOLOGY SERVICE   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

^c UNIVERSITY OF NEW SOUTH WALES   (Australia)

^d ROYAL WOMEN'S HOSPITAL   (Australia)

^e ROYAL CHILDREN'S HOSPITAL   (Australia)

^f UNIVERSITY OF MELBOURNE   (Australia)

^g UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

cervical cancer; genital warts; Pap smears; recurrent respiratory papillomatosis; vaccination; vaccine safety

Indexed keywords

WART VIRUS VACCINE;

AUSTRALIA; CANCER IMMUNIZATION; CANCER INCIDENCE; CANCER MORTALITY; CANCER REGISTRY; CANCER SCREENING; CONDYLOMA ACUMINATUM; DISEASE CONTROL; DISEASE SURVEILLANCE; DRUG EFFICACY; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; GENOTYPE; HEALTH BELIEF; HEALTH CARE QUALITY; HEALTH PROGRAM; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 11; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; HUMAN PAPILLOMAVIRUS TYPE 6; INFECTION CONTROL; PAPANICOLAOU TEST; PAPILLOMATOSIS; PAPILLOMAVIRUS INFECTION; PATIENT ATTITUDE; PREVALENCE; REVIEW; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA IN SITU; UTERINE CERVIX CYTOLOGY;

ADOLESCENT; ADULT; AGED; AUSTRALIA; CERVICAL INTRAEPITHELIAL NEOPLASIA; CHILD; CONDYLOMATA ACUMINATA; CROSS-SECTIONAL STUDIES; DRUG TOXICITY; FEMALE; HEALTH KNOWLEDGE, ATTITUDES, PRACTICE; HUMAN PAPILLOMAVIRUS 11; HUMAN PAPILLOMAVIRUS 16; HUMAN PAPILLOMAVIRUS 18; HUMAN PAPILLOMAVIRUS 6; HUMANS; INCIDENCE; MASS VACCINATION; MIDDLE AGED; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; POPULATION SURVEILLANCE; PRODUCT SURVEILLANCE, POSTMARKETING; RESPIRATORY TRACT INFECTIONS; SEXUALLY TRANSMITTED DISEASES, VIRAL; UTERINE CERVICAL NEOPLASMS; VAGINAL SMEARS; YOUNG ADULT;

EID: 77956039719     PISSN: 14485028     EISSN: None     Source Type: Journal    
DOI: 10.1071/SH09137     Document Type: Review

References (38)

1. Leask J, Jackson C, Trevena L, McCaffery K, Brotherton J. Implementation of the Australian HPV vaccination program for adult women: qualitative key informant interviews. Vaccine 2009; 27: 5505-5512 doi:10.1016/j.vaccine.2009.06. 102
2. Garland SM, Brotherton JML, Skinner SR, Pitts M, Saville M, Mola G, et al. Human papillomavirus and cervical cancer in Australasia and Oceania: risk-factors, epidemiology and prevention. Vaccine 2008; 26: M80-8. doi:10.1016/j.vaccine.2008.05.041
3. AIHW. Cervical screening in Australia 2006-2007. Cancer series No. 47. Cat. No. CAN43. Canberra: AIHW; 2009.
4. Markowitz LE, Hariri S, Unger ER, Saraiya M, Datta SD, Dunne EF. Post-licensure monitoring of HPV vaccine in the United States. Vaccine 2010; in press. doi:10.1016/j.vaccine.2010.02.019
5. CDC. Updated guidelines for evaluating public health surveillance systems. MMWR Recomm Rep 2001; 50: 1-35. RR13
6. World Health Organization. Human papillomavirus vaccines WHO position paper. Wkly Epidemiol Rec 2009; 84: 118-131
7. Siegrist C, Lewis E, Eskola J, Evans S, Black S. Human papilloma virus immunization in adolescent and young adults: a cohort study to illustrate what events might be mistaken for adverse reactions. Pediatr Infect Dis J 2007; 26: 979-984 doi:10.1097/INF.0b013e318149dfea (Pubitemid 350287577)
8. Heley S, Brotherton J. Ive had the HPV vaccine: why is my Pap test abnormal? Aust Fam Physician 2009; 38: 977-979
9. WHO. Summary of HPV surveillance and monitoring meeting, 6-7 May 2009, Geneva, Switzerland. Version: 20 July 2009. Available online at: Report-May-2009.pdf [verified June 2010]
10. Wilkinson DE, Baylis SA, Padley D, Heath AB, Ferguson M, et al. Establishment of the 1st World Health Organization international standards for human papillomavirus type 16 DNA and type 18 DNA. Int J Cancer 2010; 126: 2969-2983
11. Canfell K. Models of cervical screening in the era of HPV vaccination. Sex Health 2010; 7: 359-367 doi:10.1071/SH10016
12. Regan DG, Philp DP, Waters EK. Unresolved questions concerning human papillomavirus infection and transmission: a modeling perspective. Sex Health 2010; 7: 368-375 doi:10.1071/SH10006
13. Gertig D, Brotherton J, Saville M. Measuring human papillomavirus (HPV) vaccination coverage and the role of the National HPV Vaccination Program Register, Australia. Sex Health 2010; in press. doi:10.1071/SH10001
14. National Health and Medical Research Council. The Australian Immunisation Handbook, 9th Edition. Canberra: Australian Government; 2008.
15. Duclos P. A global perspective on vaccine safety. Vaccine 2004; 22: 2059-2063 doi:10.1016/j.vaccine.2004.01.010 (Pubitemid 38581080)
16. Lawrence G. National Vaccine Safety Workshop: summary and draft recommendations. Commun Dis Intell 2006; 30: 378-380
17. Gold M, Buttery J, McIntyre P. Human papillomavirus vaccine safety in Australia: experience to date and issues for surveillance. Sex Health 2010; 7: 320-324 doi:10.1071/SH09153
18. Lawrence G, Gold MS, Hill R, Deeks S, Glasswell A, McIntyre PB. Annual report: surveillance of adverse events following immunization in Australia, 2007. Commun Dis Intell 2008; 32: 371-387
19. Stevens M, Tabrizi SN, Brotherton J, Condon J, McIntyre P, Smith D, et al. HPV genotype prevalence among Australian women prior to vaccine implementation. Poster 26.026. 25th International Papillomavirus Conference, May 8-14, 2009. Malmo, Sweden.
20. Stevens M, Tabrizi S, Quinn M, Garland S. Human papillomavirus genotype prevalence in cervical biopsies from women diagnosed with cervical intraepithelial neoplasia or cervical cancer in Melbourne, Australia. Int J Cancer 2006; 16: 1017-1024 doi:10.1111/j.1525-1438.2006.00453.x (Pubitemid 43886720)
21. Brestavoc B, Harnett G, Smith D, Frost F, Shellam G. Human papillomavirus genotypes and their association with cervical neoplasia in a cohort of Western Australian women. J Med Virol 2005; 76: 106-110 doi:10.1002/jmv.20330 (Pubitemid 40446463)
22. Castle PE, Schiffman M, Wheeler CM, Solomon D. Evidence for frequent regression of cervical intraepithelial neoplasia-grade 2. Obstet Gynecol Surv 2009; 64: 306-308 doi:10.1097/01.ogx.0000347 334.07172.51
23. Mitchell H, Hocking J. Influences on the risk of recurrent high grade cervical abnormality. Int J Gynecol Cancer 2002; 12: 728-734 doi:10.1046/j.1525-1438.2002.01153.x (Pubitemid 35388041)
24. Brotherton JML. How much cervical cancer in Australia is vaccine preventable? A meta-analysis. Vaccine 2008; 26: 250-256 doi:10.1016/ j.vaccine.2007.10.057
25. Clifford G, Smith J, Aguado T, Franceschi S. Comparison of HPV type distribution in high-grade cervical lesions and cervical cancer: a meta-analysis. Br J Cancer 2003; 89: 101-105 doi:10.1038/sj.bjc. 6601024
26. Clifford G, Rana R, Franceschi S, Smith J, Gough G, Pimenta J. Human papillomavirus genotype distribution in low-grade cervical lesions: comparison by geographic region and with cervical cancer. Cancer Epidemiol Biomarkers Prev 2005; 14: 1157-64. doi:10.1158/ 1055-9965.EPI-04-0812
27. Alam N, Banks C, Chen W, Baker D, Kwaan G, Bishop J. Cervical cancer screening in New South Wales: annual statistical report 2005. Sydney: Cancer Institute NSW; 2008.
28. Budd A, Sturrock A. Cytology and cervical cancer surveillance in an era of human papillomavirus vaccination. Sex Health 2010; 7: 328-334 doi:10.1071/SH09133
29. Garland SM, Steben M, Sings HL, James M, Lu S, Railkar R, et al. Natural history of genital warts: analysis of the placebo arm of 2 randomized phase III trials of a quadrivalent HPV (types 6, 11, 16, 18) vaccine. J Infect Dis 2009; 119: 1-10.
30. Garland S, Hernandez-Avila M, Wheeler CM, Perez G, Harper DM, Leodolter S, et al. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med 2007; 356: 1928-1943 doi:10.1056/NEJMoa061760 (Pubitemid 46740303)
31. Fairley CK, Hocking JS, Gurrin LC, Chen MY, Donovan B, Bradshaw CS. Rapid decline in presentations of genital warts after the implementation of a national quadrivalent human papillomavirus vaccination programme for young women. Sex Transm Infect 2009; 85: 499-502. doi:10.1136/sti.2009.037788
32. Derkay CS, Wiatrak B. Recurrent respiratory papillomatosis: a review. Laryngoscope 2008; 118: 1236-1247 doi:10.1097/MLG.0b013e318 16a7135
33. Rosenthal DA, Dyson S, Pitts M, Garland SM. Challenges to accepting a human papillomavirus (HPV) vaccine: a qualitative study of Australian women. Womens Health 2007; 45: 59-73. doi:10.1300/J013v45n02-04
34. Pitts MK, Dyson SJ, Rosenthal DA, Garland SM. Knowledge and awareness of human papillomavirus (HPV): attitudes towards HPV vaccination among a representative sample of women in Victoria, Australia. Sex Health 2007; 4: 177-180 doi:10.1071/SH07023 (Pubitemid 47339642)
35. Brewer NT, Fazekas KI. Predictors of HPV vaccine acceptability: a theory-informed, systematic review. Prev Med 2007; 45: 107-114 doi:10.1016/j.ypmed.2007.05.013 (Pubitemid 47348081)
36. Cooper Robbins SC, Bernard D, McCaffery K, Brotherton J, Garland S, Skinner SR. "Is cancer contagious?" Australian adolescent girls and their parents: making the most of limited information about HPV and HPV vaccination. Vaccine 2010; 28: 3398-3408 doi:10.1016/j.vaccine. 2010.02.078
37. Donovan B, Fairley C. What can surveillance of genital warts tell us? Sex Health 2010; 7: 325-327 doi:10.1071/SH09145
38. Novakovic D, Cheng ATL, Cope DH, Brotherton JML. Estimating the prevalence of and treatment patterns for juvenile onset recurrent respiratory papillomatosis in Australia pre-vaccination: a pilot study. Sex Health 2010; 7: 253-261 doi:10.1071/SH09142